Outcomes for PTCL: which pathway to success?

Julie M. Vose

doi:10.1182/blood.2020009850

Outcomes for PTCL: which pathway to success?

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	2570-2571
Number of pages	2
Journal	Blood
Volume	137
Issue number	19
DOIs	https://doi.org/10.1182/blood.2020009850
State	Published - May 13 2021

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2020009850

Cite this

@article{b8b66798327841469d2bc3c9864b6808,

title = "Outcomes for PTCL: which pathway to success?",

author = "Vose, {Julie M.}",

note = "Funding Information: Conflict-of-interest disclosure: The author has received research/grant support from Astra-Zeneca, Incyte Corp, Kite Pharma, Novartis, Seattle Genetics, Loxo, and Epizyme and has received consultancy fees/honorarium from Abbvie, Epizyme, Vandiam Group, Janssen/Pharmacyclics, Kite Pharma, Astra-Zeneca, Verastem, Miltenyi, Loxo, Allogene, Wugene, Celgene, Roche, Genentech, Karyopharm, and Morphosis.",

year = "2021",

month = may,

day = "13",

doi = "10.1182/blood.2020009850",

language = "English (US)",

volume = "137",

pages = "2570--2571",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "19",

}

TY - JOUR

T1 - Outcomes for PTCL

T2 - which pathway to success?

AU - Vose, Julie M.

N1 - Funding Information: Conflict-of-interest disclosure: The author has received research/grant support from Astra-Zeneca, Incyte Corp, Kite Pharma, Novartis, Seattle Genetics, Loxo, and Epizyme and has received consultancy fees/honorarium from Abbvie, Epizyme, Vandiam Group, Janssen/Pharmacyclics, Kite Pharma, Astra-Zeneca, Verastem, Miltenyi, Loxo, Allogene, Wugene, Celgene, Roche, Genentech, Karyopharm, and Morphosis.

PY - 2021/5/13

Y1 - 2021/5/13

UR - http://www.scopus.com/inward/record.url?scp=85105731823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105731823&partnerID=8YFLogxK

U2 - 10.1182/blood.2020009850

DO - 10.1182/blood.2020009850

M3 - Editorial

C2 - 33983423

AN - SCOPUS:85105731823

SN - 0006-4971

VL - 137

SP - 2570

EP - 2571

JO - Blood

JF - Blood

IS - 19

ER -

Outcomes for PTCL: which pathway to success?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this